International Assets Investment Management LLC Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

International Assets Investment Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,597 shares of the company’s stock after purchasing an additional 632 shares during the period. International Assets Investment Management LLC’s holdings in Eli Lilly and Company were worth $7,343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of LLY. JGP Wealth Management LLC lifted its holdings in Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares during the last quarter. Valley Wealth Managers Inc. boosted its holdings in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares during the period. Sandy Cove Advisors LLC grew its stake in Eli Lilly and Company by 0.8% in the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after buying an additional 17 shares in the last quarter. Convergence Investment Partners LLC grew its stake in Eli Lilly and Company by 1.3% in the 3rd quarter. Convergence Investment Partners LLC now owns 1,419 shares of the company’s stock valued at $762,000 after buying an additional 18 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC raised its holdings in Eli Lilly and Company by 0.4% during the 3rd quarter. Cassaday & Co Wealth Management LLC now owns 4,618 shares of the company’s stock valued at $2,480,000 after acquiring an additional 18 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $766.74 on Tuesday. The company has a market capitalization of $728.72 billion, a P/E ratio of 112.92, a PEG ratio of 1.45 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a 50 day moving average price of $760.96 and a two-hundred day moving average price of $673.52.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.62 EPS. Analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.